September 7, 2021, Palo Alto, California – I Peace, Inc. (CEO: Koji Tanabe), a Palo Alto-based biotech startup focusing on Nobel Prize-winning technology of induced pluripotent stem cells (iPSCs) expands its personalized iPSC banking service. I Peace launched its clinical-grade personalized iPSC banking service in 2020 in Japan and has already banked several individuals’ iPSCs. The company will collaborate with I’rom Group Co., Ltd. (Japan) to make the service available for clients at every corner of the country. Using this as proof of concept,  I Peace plans to launch the iPSC banking service in the U.S. as the next phase of its business expansion. [Read more…]
Meet the New York Scientist Using Stem Cells as a Treatment For MS
Treatment for multiple sclerosis (MS) is an evolving area and one in which new therapeutic approaches are rapidly advancing. Led by Dr. Saud Sadiq, the Tisch MS Research Center of New York is pursuing a Phase II clinical trial exploring the use of stem cell technology for the treatment for MS. The announcement followed positive results from an FDA-approved Phase I stem cell trial for MS. [Read more…]
Jacobio Enters Strategic Investment with Hebecell to Develop iPSC-derived NK Cell Therapy
BEIJING and SHANGHAI and BOSTON, Aug. 31, 2021 — Jacobio Pharmaceuticals (“Jacobio”, 1167.HK) announced a strategic investment in the US-based biotech company Hebecell on August 31. Jacobio will collaborate with Hebecell to develop the next-generation natural killer cell therapy based on induced pluripotent stem cells (iPSC-NK).
Once the deal is completed, Jacobio chairman and CEO Dr. Yinxiang Wang will be appointed as Chairman of Hebecell. [Read more…]
Nearly $10 Billion Pours Into Cell & Gene Therapy Contract Manufacturing Infrastructure
Currently, the cell and gene therapy (CGT) field is on track for a serious capacity shortage. In particular, there is a significant shortage of manufacturing capacity at the commercial scale. Although nearly 90% of cell and gene therapy developers would prefer to use contract manufacturing organizations (CMOs), relevant CMO capacity is not yet available. [Read more…]
Largest European Cord Blood Bank Acquires Majority Ownership of Smart Cells Holdings
-
FamiCord Group is investing in a stem cell bank owned by Smart Cells Holdings Limited, UK, acquiring 84.2% of shares.
-
After the transaction, FamiCord Group will store 610,000 samples belonging to over 450,000 families.
WARSAW, Poland, Aug. 31, 2021 — Polski Bank Komórek Macierzystych S.A. (PBKM), which leads the international FamiCord Group, Europe’s largest stem cell bank, signed a transaction agreement with shareholders of Smart Cells Holdings Limited, based in London UK. [Read more…]
- « Previous Page
- 1
- …
- 158
- 159
- 160
- 161
- 162
- …
- 336
- Next Page »